Adult Dosing

Superficial infections

• Apply bid-tid to the affected area
• Max: 5 times/day; 7 days duration

Pediatric Dosing

Superficial infections

• Apply bid-tid to the affected area
• Max: 5 times/day; 7 days duration

• Topical treatment of localized skin infections
• Prevention of wound infections

• Hypersensitivity to bacitracin or any component of the formulation

• N/A

Renal Dose Adjustment

• Renal impairment: None required

Hepatic Dose Adjustment

• Hepatic impairment: None required

• Prolonged use may result in bacterial or fungal overgrowth of nonsusceptible microorganisms
• Do not use for >7 consecutive days

Cautions: Use cautiously in

• Systemic infections
• Antibiotic allergies
• Myasthenia gravis
• Lactation

Pregnancy Category:C

Breastfeeding: Poorly excreted in breast milk; considered a low risk to the nursing infant. Water-miscible ointments applied to the breast may expose the infant to high levels of mineral paraffins via licking. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 17 August 2010).

• DERM: Contact dermatitis, local burning, redness, rash

• Polypeptide antibiotic; interferes with bacterial cell wall synthesis; active against bacterial protoplasts and also damages the bacterial plasma membrane
• Minimal systemic absorption
• Not metabolized significantly; CYP450: None
• Renally excreted: Unknown
• Half life: Unknown

US Trade Name(s)

• Only generic available

US Availability

bacitracin (generic)

• OINT: 500 units/g

Canadian Trade Name(s)

• Bacitin

Canadian Availability

bacitracin (generic)

• OINT: 500 units/g

Bacitin

• OINT: 500 units/g

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Dermatologic

Dermatologic Topical Agents

Miscellaneous Agents